Stem Cell Therapy for Patients With Vascular Occlusive Diseases Such as Diabetic Foot
NCT ID: NCT02304588
Last Updated: 2014-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
20 participants
INTERVENTIONAL
2013-01-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mesenchymal stem cells
Maximal amount of MSC cells injected: 10-20\*10\^6 cells (up to volume of 20mL, depending on the wound size \& patient weight).
Mesenchymal stem cells
10-20 x 10\^6 cells/20mL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mesenchymal stem cells
10-20 x 10\^6 cells/20mL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* in accordance with the ministry of health in higher medical colleges and universities teaching material the sixth edition of the annals of diabetic foot diagnostic criteria.
* with severe lower limb ischemia (defined as the resting state of ankle brachial index (ABI) 0.4-0.85, accompanied by resting or intermittent toe line.
* treatment on a voluntary basis, and sign the informed consent.
Exclusion Criteria
* clear over the past five years tumor markers in patients with malignant disease and blood levels increased significantly.
* the prodrome of acute infectious diseases.
* participated in clinical subjects within three months before test.
* adherence is poor, can not complete the course.
30 Years
78 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaobing Fu
Academician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
xiaobing FU
Role: PRINCIPAL_INVESTIGATOR
Chinese PLA General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
xiaobing FU
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
haojie Hao
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHIN-PLAGH-ST-001
Identifier Type: -
Identifier Source: org_study_id